8-K: BioCardia Reports Promising CardiAMP HF Trial Results and First Quarter 2025 Financials

BioCardia announces positive two-year results from its CardiAMP HF Trial and reports its first quarter 2025 financial results, highlighting progress in its cardiovascular and pulmonary disease therapies.

Summary

• BioCardia reported its financial results for the first quarter of 2025.
• Two-year results from the CardiAMP HF Trial showed increased survival and decreased cardiovascular events for treated patients.
• Statistically significant improvements were observed in patients with active heart stress.
• The company is preparing to share the two-year data with the FDA and Japan PMDA.
• The CardiAMP HF II Trial is underway in the United States, focusing on patients with active heart stress.
• Results from the open-label roll-in cohort of patients with refractory angina showed improvements in exercise tolerance and reduction in angina episodes.
• The low dose cohort of the CardiALLO Cell Therapy trial was completed with no treatment-emergent adverse events.
• The company plans to progress the CardiALLO trial to enrollment of 39 participants.
• BioCardia's Helix delivery system performed well in the CardiAMP HF Trial.
• The company's intellectual property portfolio includes more than 60 patents and patent applications worldwide.
• Research and development expenses were approximately $1.5 million for the three months ended March 2025.
• Selling, general and administrative expenses were approximately $1.2 million for the three months ended March 2025.
• The net loss was approximately $2.7 million for the three months ended March 2025.
• Net cash used in operations for the three months ended March 2025 was approximately $1.6 million.
• The company anticipates upcoming milestones including regulatory submissions and trial advancements.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. Positive clinical trial results are tempered by increased losses and decreased cash reserves. The company is making progress but faces financial challenges.

Positives

• The CardiAMP HF Trial showed positive two-year results, indicating increased survival and decreased cardiovascular events.
• The CardiAMP HF II Trial is underway, focusing on a specific patient subset with active heart stress.
• The CardiALLO Cell Therapy trial's low dose cohort was completed with no adverse events, allowing the trial to progress.
• The company's intellectual property portfolio is robust, with more than 60 patents and patent applications worldwide.
• The Helix delivery system performed well in the CardiAMP HF Trial, supporting its independent FDA submission.

Negatives

• The company reported a net loss of approximately $2.7 million for the three months ended March 2025, compared to a net loss of approximately $2.3 million for the three months ended March 2024.
• Net cash used in operations for the three months ended March 2025 was approximately $1.6 million, as compared to approximately $1.5 million for the three months ended March 2024.
• The company's cash and cash equivalents decreased from $2.371 million at the end of 2024 to $949 thousand at the end of March 2025.

Risks

• The company faces inherent uncertainties associated with developing new products and technologies.
• Regulatory approvals are not guaranteed and can be subject to delays.
• The company may face unexpected expenditures.
• The company's ability to raise additional funding is uncertain.
• The company's ability to enter into licensing and partnering arrangements is not guaranteed.
• Overall market conditions could impact the company's performance.
• Slower than targeted enrollment could delay completion of clinical trials.

Future Outlook

BioCardia anticipates upcoming milestones including regulatory submissions for CardiAMP and Helix, advancements in clinical trials, and partnering opportunities.

Management Comments

• This has been a great quarter for all of our therapeutic programs in development, said BioCardia CEO Peter Altman, Ph.D.
• Most importantly, the CardiAMP HF Trial has provided significant rigorous evidence supporting both safety and meaningful benefits of CardiAMP cell therapy for heart failure patients who still have elevated biomarkers of heart stress, despite being on maximal guideline directed medical therapy.
• Our top priorities are the regulatory submissions for the CardiAMP Cell Therapy System clinical consultation with Japan PMDA and for the Helix transendocardial delivery system application for approval in the United States.
• Both are anticipated this quarter.

Industry Context

BioCardia is operating in the competitive field of cell-based therapies for cardiovascular and pulmonary diseases, where companies like Mesoblast and Vericel are also developing advanced therapies. The positive results from the CardiAMP HF Trial could position BioCardia as a leader in treating heart failure patients with elevated biomarkers of heart stress.

Comparison to Industry Standards

• Mesoblast's Revascor is another cell therapy targeting heart failure, but with a different mechanism of action.
• Vericel's Carticel is a cell therapy for cartilage repair, demonstrating the potential of cell therapies in regenerative medicine.
• BioCardia's focus on patients with elevated biomarkers of heart stress differentiates its approach from other heart failure therapies.

Stakeholder Impact

• Shareholders may be encouraged by the positive clinical trial results but concerned about the increased losses and decreased cash reserves.
• Employees may be motivated by the progress in clinical trials but concerned about the company's financial stability.
• Patients may benefit from the potential approval of new therapies for heart failure and other cardiovascular diseases.
• Investors may be interested in the company's progress but cautious about the financial risks.

Next Steps

• The company will submit the CardiAMP HF manuscript for presentation/publication.
• The company will request/submit a clinical consultation with Japan PMDA.
• The company will request/submit an FDA meeting.
• The company will add additional sites and enroll more patients in the CardiAMP Heart Failure II Trial.
• The company will submit completed roll-in cohort data for presentation/publication.
• The company will complete enrollment of dose cohort 2 in the CardiAllo Allogeneic Cell Therapy trial.
• The company will pursue FDA approval milestones for the Helix Biotherapeutic Delivery Business.
• The company will seek partnering opportunities for the Helix Biotherapeutic Delivery Business.
• The company will focus on revenues and case reports for the Morph Access Innovations Business.
• The company will seek indication specific deals for the Morph Access Innovations Business.

Key Dates

Keywords

BioCardia, CardiAMP, CardiALLO, Helix, Heart Failure, Cell Therapy, Financial Results, Clinical Trial, Cardiovascular Disease, Pulmonary Disease